Advanced and experienced hematology and cancer care.
Oncology Specialists of Charlotte Welcomes Dr. Nasfat J. Shehadeh to the practice!
Learn More
Clinical Trials

Oncology Specialists of Charlotte has partnered with DJL Clinical Research, a local investigative site network, which was founded by two independent physicians who have participated in medical research and served patients in Charlotte and Union County for over 35 years.

If you, a family member or a loved one would like to determine eligibility, please have them call or e-mail to inquire: 704-247-9179, jen.ponder@djlresearch.com. Research patients do not have to be patients of the practice.


Multiple Myeloma

Disease registry encompassing the care of patients with multiple myeloma on panobinostat.

  • To describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat
  • To characterize adverse events (AEs) in myeloma patients who are initiating treatment with panobinostat or changing treatment to panobinostat in the first or later lines of therapy
  • To assess patient-reported outcomes and it’s association with therapeutic treatment patterns and clinical outcomes in myeloma patients who are initiating treatment RECOMM Registry Version 1.1 Page 7 with panobinostat or changing treatment to panobinostat in the first or later lines of therapy

Non-small Cell Lung Cancer

Phase 3 study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy for patients that have remained stable or responded to first line platinum based chemo plus pebrolizumab for stage IIIB or non-small cell lung cancer.

Who's Eligible?
  • Participants must be at least 18 years of age
  • Has a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either nonsquamous or squamous histology; mixed histology is allowed)
  • Has completed at least 4 but no more than 6 cycles of platinum-based first-line induction chemotherapy with pembrolizumab
Who's Eligible?
  • Participants must be at least 18 years of age
  • Has a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either nonsquamous or squamous histology; mixed histology is allowed)
  • Has completed at least 4 but no more than 6 cycles of platinum-based first-line induction chemotherapy with pembrolizumab
Cutaneous Squamous Cell Carcinoma

Describe the long-term real-world use and effectiveness of cemiplimab for cutaneous squamous cell carcinoma.

Who's Eligible?
  • Men and women ages 18+ who recently initiated, or are planning to initiate treatment with commercially available cemiplimab for CSCC in a real-world setting.
Who's Eligible?
  • Men and women ages 18+ who recently initiated, or are planning to initiate treatment with commercially available cemiplimab for CSCC in a real-world setting.
Non-Small Cell Lung

Pivotal, randomized, open-label study of Tumor Treating Fields concurrent with standard-of-care therapies for treatment of stage 4 non-small cell lung Cancer (NSCLC) following platinum failure.

Who's Eligible?
  • Patients with a histology-based diagnosis of stage 4 NSCLC
  • Age of 22+
  • Progression on or after receiving platinum-based chemotherapy
Who's Eligible?
  • Patients with a histology-based diagnosis of stage 4 NSCLC
  • Age of 22+
  • Progression on or after receiving platinum-based chemotherapy
Subscribe to our Newsletter!

Signup today for free and be the first to get notified on new updates.